

# Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis

Rasha Khatib,<sup>1</sup> Maja Ludwikowska,<sup>2</sup> Daniel M. Witt,<sup>3</sup> Jack Ansell,<sup>4</sup> Nathan P. Clark,<sup>5</sup> Anne Holbrook,<sup>6</sup> Wojtek Wiercioch,<sup>7</sup> Holger Schönemann,<sup>7</sup> and Robby Nieuwlaat<sup>7</sup>

<sup>1</sup>Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL; <sup>2</sup>Evidence Prime Inc, Cracow, Poland; <sup>3</sup>Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT; <sup>4</sup>Hofstra Northwell School of Medicine, Hempstead, NY; <sup>5</sup>Clinical Pharmacy Anticoagulation and Anemia Service, Kaiser Permanente Colorado, Aurora, CO; and <sup>6</sup>Division of Clinical Pharmacology & Toxicology, Department of Medicine, and <sup>7</sup>Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada

Patients receiving vitamin K antagonists (VKAs) with an international normalized ratio (INR) between 4.5 and 10 are at increased risk of bleeding. We systematically reviewed the literature to evaluate the effectiveness and safety of administering vitamin K in patients receiving VKA therapy with INR between 4.5 and 10 and without bleeding. Medline, Embase, and Cochrane databases were searched for relevant randomized controlled trials in April 2018. Search strategy included terms vitamin K administration and VKA-related terms. Reference lists of relevant studies were reviewed, and experts in the field were contacted for relevant papers. Two investigators independently screened and collected data. Risk ratios (RRs) were calculated, and certainty of the evidence was assessed using Grading of Recommendations Assessment, Development and Evaluation. Six studies (1074 participants) were included in the review and meta-analyses. Pooled estimates indicate a nonsignificant increased risk of mortality (RR = 1.42; 95% confidence interval [CI], 0.62-2.47), bleeding (RR = 2.24; 95% CI, 0.81-7.27), and thromboembolism (RR = 1.29; 95% CI, 0.35-4.78) for vitamin K administration, with moderate certainty of the evidence resulting from serious imprecision as CIs included potential for benefit and harm. Patients receiving vitamin K had a nonsignificant increase in the likelihood of reaching goal INR (1.95; 95% CI, 0.88-4.33), with very low certainty of the evidence resulting from serious risk of bias, inconsistency, and imprecision. Our findings indicate that patients on VKA therapy who have an INR between 4.5 and 10.0 without bleeding are not likely to benefit from vitamin K administration in addition to temporary VKA cessation.

## Introduction

Vitamin K antagonists (VKAs) are used to prevent and treat venous thromboembolism (VTE) and to prevent arterial thromboembolism in patients with atrial fibrillation or cardiac disease, including mechanical heart valves.<sup>1,2</sup> The international normalized ratio (INR), which measures the intensity of VKA anticoagulant effect, is commonly used to monitor VKA therapy. Despite monitoring and careful dose adjustment, INR values outside the target range are frequently observed.<sup>3</sup>

High INR values have been associated with increased bleeding risk and therefore, at some threshold, need to be corrected.<sup>4-6</sup> Vitamin K has been commonly used to normalize high INR values. VKAs act by inhibiting vitamin K-dependent  $\gamma$ -carboxylation of coagulation factors II, VII, IX, and X. Exogenously

administered vitamin K (available commercially as phytonadione) normalizes the INR by providing the necessary substrate to synthesize these coagulation factors.<sup>7,8</sup>

Two systematic reviews on this topic were published in 2006 and concluded that vitamin K may be effective in reducing elevated INR values. One of these reviews did not pool estimates from individual studies and reported narrative results only.<sup>9</sup> The other review pooled individual study results and concluded that oral and IV vitamin K effectively reduce follow-up INRs measured within 24 hours to <4.0 in about three-quarters of patients with excessive VKA anticoagulation. These reviews did not investigate effects on bleeding or other patient-important outcomes.<sup>9-12</sup>

Clinical practice guideline recommendations regarding the optimal management of patients with excessive VKA anticoagulation have evolved over time. Early guidelines dating back to 1995 recommended subcutaneous administration of vitamin K when rapid reversal is required because of elective surgery or if the INR is between 6.0 and 10.0.<sup>13</sup> Later guideline recommendations changed to administering oral vitamin K in these instances.<sup>1</sup> As of 2008, guidelines were changed and recommended against the administration of vitamin K for patients with INRs between 4.5 and 10.0 who have no significant bleeding, in addition to withholding the next 1 or 2 doses of VKA with more frequent INR monitoring.<sup>14</sup> We aimed to update the literature on this topic by answering the following question for the American Society of Hematology clinical practice guidelines on VTE: In patients receiving VKA presenting with an INR between 4.5 and 10 and without bleeding, should vitamin K in addition to temporary cessation of VKA be used to reverse excessive anticoagulation compared with temporary cessation of VKA alone?

## Methods

This systematic review was performed as part of the American Society of Hematology guidelines on VTE, developed in partnership with the McMaster University's Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre. Review and meta-analysis methodology followed the Cochrane Handbook,<sup>14</sup> with reporting according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.<sup>15</sup>

## Search strategy

MEDLINE (1996 to week 2 of April 2018), EMBASE (1974 to week 2 of April 2018), and the Cochrane Central Register of Controlled Trials (until week 2 of April 2018) were searched. The search strategy consisted of keywords specific to each database and was restricted to randomized controlled trials (RCTs) of human subjects but not restricted by language. The MEDLINE search strategy is provided in supplemental Material 1. Additionally, the reference lists of relevant studies and reviews were reviewed, and clinical experts in the field of anticoagulation management were consulted for additional references.

## Study selection

Two reviewers (R.K. and M.L.) independently screened titles, abstracts, and the full text of relevant articles based on prespecified inclusion and exclusion criteria. Disagreements were resolved by consensus and by a third reviewer when needed (R.N.). RCTs were included if they fulfilled the following criteria.

**Table 1. Characteristics of included studies**


Reference	Country	No. of randomized patients	Baseline INR	Type of VKA	VKA indication	Treatment*	Follow-up duration, d
Fondevilla 2001 <sup>22</sup>	Argentina	109	Treatment, 8.4 (6.0-19.6); control, 8.1 (6.0-14.1)	A	NR	Intervention, 1 mg oral vitamin K; comparison: observation	7
Crowther 2000 <sup>20</sup>	Canada	92	Treatment, 5.4 (4.5-9.8); control, 5.9 (4.5-9.8)	W	NR	Intervention, 1 mg oral vitamin K; comparison: placebo	30
Patel 2000 <sup>17†</sup>	United States	30	Treatment, 7.2 (6.0-9.2); control, 7.0 (6.1-9.5)	W	VTE, 27%; AF, 44%; CVD, 7%; LVD, 13%; other, 10%	Intervention, 2.5 mg oral vitamin K; comparison: placebo	Not specified
Ageno 2002 <sup>19</sup>	Italy, Canada	60	Treatment, 6.2; control, 6.0	A	VTE, 32%; AF, 67%; stroke prophylaxis, 1%	Intervention, 1 mg oral vitamin K; comparison: observation	30
Ageno 2005 <sup>18</sup>	Italy, United States	59	Treatment, 7.2; control, 7.7	W	Mechanical heart valve, 100%	Intervention, 1 mg oral vitamin K; comparison: observation	30
Crowther 2009 <sup>21</sup>	Canada, United States, Italy	724	Treatment, 6.0 (4.5-9.9); control, 5.8 (4.5-9.5)	W	Thromboembolism treatment or prevention, AF, or artificial heart valve†	Intervention, 1.25 mg oral vitamin K; comparison: placebo	90

A, acenocoumarol; AF, atrial fibrillation; CVD, cardiovascular disease; LVD, left ventricular dysfunction; NR, not reported; W, warfarin.

\*All included studies withheld vitamin K antagonist administration in the treatment and control groups.

†Study fulfilled the inclusion criteria but reported 0 events and was therefore not included in the meta-analysis.

#Patients may have more than 1 indication for VKA.



**Figure 1. All-cause mortality.** —, low risk of bias; +, high risk of bias; ?, unknown risk of bias; df, degree of freedom; M-H, Mantel Haenszel; trt, treatment.

**Patients.** Adult patient population ( $\geq 18$  years of age) using VKAs with a first episode of an elevated INR value (between 4.5 and 10) that required temporary VKA cessation and without bleeding. Patients who required VKA reversal for urgent surgery or because of bleeding were excluded. Studies were included with patients taking VKA for any indication.

**Intervention.** Administration of vitamin K (oral, IV, or subcutaneous) at any dose.

**Comparison.** Placebo or observation only.

**Outcomes.** All-cause mortality, major bleeding, thromboembolism, and proportion of patients reaching goal INR assessed at 24 hours and at 1 week of vitamin K administration.

**Study design.** Only RCTs were included.

## Data abstraction and quality assessment

One reviewer (M.L.) collected data from each eligible study using a pretested data abstraction form, and data were checked by another reviewer (R.K.) to assess accuracy. Disagreements were resolved by discussion, and by a third reviewer (R.N.) when needed. The data collected included patient characteristics (baseline INR values and VKA indication), vitamin K treatment (dose, route, and frequency of administration), study setting, follow-up, and outcomes. Information on risk of bias was also collected and assessed for each outcome in each included study using the Cochrane risk of bias tool for RCTs.<sup>16</sup> Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated by pooling the results from RCTs using the Mantel Haenszel method and the random effects model. Heterogeneity was assessed using the I<sup>2</sup> index and was deemed as moderate to high with an I<sup>2</sup> > 50%.<sup>16</sup> Data were analyzed using RevMan 5.3.

Two reviewers evaluated the certainty of the evidence for each outcome using the GRADE approach.<sup>17</sup> The certainty of the evidence was assessed as high, moderate, low, or very low and summarized in a GRADE Evidence Profile.

## Results

### Search results

A total of 4327 unique citations were identified from the electronic database search and from other sources. Based on title and abstract

screening, 3555 citations were excluded. An additional 12 citations were excluded based on full-text screening. Reasons for excluding full-text citations included: inclusion criteria did not restrict INR range to 4.5 to 10.0, VKA was continued in the intervention arm, vitamin K was administered in the control arm, duplicate trial data, not an RCT, or published in abstract only (supplemental Material 2). Six studies were included in this systematic review after nonrelevant citations were excluded. One study<sup>18</sup> reported 0 events for the outcomes of interest. This study was not included in the meta-analysis because it did not provide any indication of either the direction or magnitude of the relative treatment effect,<sup>16</sup> leaving 5 studies for inclusion in the meta-analyses.

### Study characteristics

Study characteristic details are included in Table 1. A total of 1074 participants were included in the 6 studies.<sup>18-23</sup> Three studies were single-center studies conducted in Argentina,<sup>23</sup> Canada,<sup>24</sup> and the United States.<sup>18</sup> The remaining 3 studies were multicenter studies conducted in Italy, Canada, and the United States.<sup>19-21</sup> Warfarin was used in the 3 studies; acenocoumarol was used in 2 studies.<sup>20,23</sup> Baseline INR values ranged from 5.4 to 8.4 in the vitamin K group, and from 5.8 to 8.1 in the control group. The vitamin K groups received oral vitamin K (dose range, 1-2.5 mg).

The control groups received placebo<sup>18,21,24</sup> or observation only.<sup>19,20,23</sup> VKA was temporarily withheld in all included studies in both the vitamin K and control groups.

### Risk of bias and synthesis of results

Overall, the risk of bias of the included studies was low. All studies randomly allocated patients using proper sequence generation, and 4 of the studies reported methods of allocation concealment.<sup>18,19,21,23,24</sup> Blinding of patients and outcome assessors was reported in 2 studies only.<sup>21,24</sup> Incomplete data were limited or properly dealt with across all studies. Forest plots (Figures 1-4) present a summary of the risk of bias for each study.

Subgroup analyses by vitamin K dose and method of vitamin K administration were prespecified, but identified data were inadequate to perform subgroup analyses. Publication bias was prespecified but could not be assessed given the small number of included studies.

## All-cause mortality

Three studies (860 randomized patients) assessed all-cause mortality during either 30 or 90 days of follow-up (Table 2).<sup>19,21,24</sup> The pooled RR was 1.42 (95% CI, 0.62-2.47) in favor of placebo, and no heterogeneity was observed ( $I^2 = 0$ , Figure 1). The certainty of the evidence, based on the GRADE criteria, was assessed as moderate because of serious imprecision in the pooled estimate.

## Major bleeding

Six studies assessed major bleeding, 4 of which reported 0 events in the treatment and control groups and were not included in the meta-analysis.<sup>18-20,23</sup> The remaining 2 studies<sup>21,24</sup> (801 randomized patients) reported major bleeding outcomes at 90 days of follow-up and were included in the meta-analysis (Table 2). The pooled RR was 2.43 (95% CI, 0.81-7.27) in favor of placebo with no observed heterogeneity ( $I^2 = 0$ ; Figure 2). The certainty of the evidence was moderate because of serious imprecision of the pooled estimate.

## Thromboembolism

Five studies assessed thromboembolism outcomes, 3 of which had 0 events in the treatment and control groups<sup>18,20,23</sup>; therefore only 2 studies were included in the meta-analysis (Table 2). The pooled RR (from 916 randomized patients) was 1.29 (95% CI, 0.35-4.78) in favor of placebo with no observed heterogeneity ( $I^2 = 0$ , Figure 3). The certainty of the evidence for any thromboembolism was assessed as moderate because of serious imprecision in the pooled estimate.

## Proportion of patients who reached goal INR

Five studies (313 randomized patients) provided information on the number of patients who reached goal INR values within 1 day of vitamin K administration (Table 2). The pooled RR of reaching goal INR values was 1.95 (95% CI, 0.88-4.33) in favor of vitamin K. Overall heterogeneity was high ( $I^2 = 93\%$ ; Figure 4) and was not explained by the different definitions of goal INR values. The certainty of the evidence was assessed as very low because of serious risk of bias primarily related to lack of blinding, serious inconsistency, and serious imprecision of the pooled estimate. Two studies also reported the number of patients who reached goal INR values after 1 week of vitamin K administration. One study reported a RR of 1.16 (95% CI, 0.67-1.99) for goal INR ranging between 2.0 and 3.0, and a RR of 1.65 (95% CI, 1.04-2.62) for goal INR ranging between 1.8 and 3.2.<sup>20</sup> Another study reported a RR of 0.78 (95% CI, 0.50-1.21) for goal INR ranging between 2.0 and 4.0.<sup>23</sup>

## Discussion

Very low to moderate quality evidence suggests that there is no additional benefit in administering vitamin K in patients who need to temporarily stop VKA because of INR elevation between 4.5 and 10.0 and who are not bleeding. The RCTs were primarily designed to detect a difference in the important surrogate outcome of achieving a targeted INR reduction, but this potential benefit was not significant and may not translate into improved clinical outcomes because the pooled RRs for mortality, major bleeding, and thromboembolism were all consistent with no effect.

**Table 2. GRADE evidence table**

No. of participants (studies)	Quality assessment					Summary of findings				
	Risk bias	Inconsistency	Indirectness	Imprecision	Publication bias	Overall quality of evidence	Study event rates (%)	Anticipated absolute effects	Risk with temporary cessation of VKA alone	Risk difference with temporary cessation of VKA + vitamin K administration (range)
<b>Mortality (follow-up: 30-90 d; assessed with all-cause mortality)</b>										
860 (3 RCTs)	NS	NS	NS	S*	None	⊕⊕⊕ Moderate	13/439 (3.0)	16/421 (3.8)	RR = 1.24 (0.62-2.47)	30 per 1000 7 more per 1000 (11 fewer-44 more)
<b>Major bleeding (follow-up: mean, 90 d; assessed with fatal bleeding or bleeding requiring blood transfusion or admission)</b>										
801 (2 RCTs)	NS	NS	NS	S*	None	⊕⊕⊕ Moderate	4/409 (1.0)	10/392 (2.6)	RR = 2.43 (0.81-7.27)	10 per 1000 14 more per 1000 (2 fewer-61 more)
<b>Any thromboembolism (follow-up: mean, 90 d; assessed with venous or arterial thromboembolism)</b>										
801 (2 RCTs)	NS	NS	NS	S*	None	⊕⊕⊕ Moderate	4/409 (1.0)	5/392 (1.3)	RR = 1.29 (0.35-4.78)	10 per 1000 3 more per 1000 (6 fewer-37 more)
<b>Proportion reaching goal INR (follow-up: mean, 1 d; assessed with INR goal ranges: INR, 1.8-3.2; INR, 2.3-4.5; and INR, 2.0-4.0)</b>										
1025 (5 RCTs)	S†	S†	NS	S*	None	⊕⊕⊕ Very low	90/518 (17.4)	218/507 (43.0)	RR = 1.95 (0.88-4.33)	174 per 1000 165 more per 1000 (21 fewer-579 more)

Overall quality of evidence measured according to GRADE criteria.

RE, relative effect; NS, not serious; S, serious.

\*Lower and upper bounds of 95% CI may lead to different recommendations.

†Four of the 5 studies did not blind patients and personnel, or outcome assessors.

# $I^2 = 93\%$ .




Figure 2. Major bleeding.

The small number and very low to moderate quality of studies included are limitations to our review. Although not statistically significant, our results indicate a trend toward more bleeding when vitamin K is administered, which was an unexpected finding. Given the small number of events and large CIs for these outcomes, it is likely that these results are due to chance alone. Bleeding with or without anticoagulation results from tissue or blood vessel damage or injury. A prospective cohort of 107 nonbleeding patients presenting with an INR >10 found only a single major bleeding event occurred within 7 days of the index INR.<sup>25</sup> Although higher INRs are associated with increased risk of bleeding,<sup>4-6</sup> there may not be a clinically important difference in INR decline or risk of bleeding over 24 to 72 hours between placebo and vitamin K.

We intended to investigate differences in the effects of vitamin K by dose, route of administration, and type; however, the small number of studies did not permit such subgroup analyses. In terms of type of VKA, 3 of the included studies used warfarin, 2 used acenocoumarol, and none used phenprocoumon. These medications have different pharmacokinetic properties, which may result in different responses to vitamin K and placebo treatment. For example, the half-life of warfarin is close to double that of acenocoumarol.<sup>20</sup>

The low level of heterogeneity in our results suggests that variations in vitamin K type, dose, or route of administration did not likely influence our observed outcomes. Publication bias could not be assessed because of the small number of studies included. Because publication bias typically causes overly optimistic effect estimates by including more positive studies, it is unlikely that this influenced our conclusions as effects tended to go into the direction of harm.

The most recent systematic review on this topic that attempted to pool individual study data focused on the proportion of patients who reached goal INR in the treatment group and did not provide relative effects or comparison data from a control group.<sup>10</sup> There were also several differences compared with our study regarding the inclusion criteria: we identified 1 recent study that was published after the previous systematic review was conducted.<sup>21</sup> In addition, we excluded 5 RCTs that the previous systematic review included. These RCTs were excluded because VKA was not temporarily discontinued in the treatment group<sup>26</sup> or because they compared different doses or routes of administration for vitamin K, rather than against placebo or observation only.<sup>22,27-29</sup> Finally, DeZee et al<sup>10</sup> included nonrandomized studies, whereas we focused on RCTs only. We estimate that the risk of bias related to




Figure 3. Any thromboembolism event.



## References

1. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [published correction appears in *Chest*. 2005;127(1):415-416]. *Chest*. 2004;126(3 suppl):204S-233S.
2. Witt DM, Clark NP, Kaatz S, Schnurr T, Ansell JE. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. *J Thromb Thrombolysis*. 2016;41(1):187-205.
3. Haas S, Ten Cate H, Accetta G, et al; GARFIELD-AF Investigators. Quality of vitamin k antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF Registry. *PLoS One*. 2016;11(10):e0164076.
4. Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DE. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. *Arch Intern Med*. 2000;160(11):1612-1617.
5. Palareti G, Leali N, Coccheri S, et al; Italian Study on Complications of Oral Anticoagulant Therapy. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). *Lancet*. 1996;348(9025):423-428.
6. Adeboyeje G, Sylwestrzak G, Barron JJ, et al. Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation. *J Manag Care Spec Pharm*. 2017;23(9):968-978.
7. Friedman PA, Rosenberg RD, Hauschka PV, Fitz-James A. A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients. *Biochim Biophys Acta*. 1977;494(1):271-276.
8. Malhotra OP, Nesheim ME, Mann KG. The kinetics of activation of normal and gamma-carboxyglutamic acid-deficient prothrombins. *J Biol Chem*. 1985;260(1):279-287.
9. Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. *J Thromb Haemost*. 2006;4(9):1853-1863.
10. Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, O'malley PG. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. *Arch Intern Med*. 2006;166(4):391-397.
11. Arbit B, Nishimura M, Hsu JC. Reversal agents for direct oral anticoagulants: a focused review. *Int J Cardiol*. 2016;223:244-250.
12. Thigpen JL, Limdi NA. Reversal of oral anticoagulation. *Pharmacotherapy*. 2013;33(11):1199-1213.
13. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. *Chest*. 1995;108(4 Suppl):231S-246S.
14. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*. 2008;133(suppl. 6):454S-545S.
15. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097.
16. Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from <http://handbook-5-1.cochrane.org/>. Accessed 18 February 2019.
17. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336(7650):924-926.
18. Patel RJ, Witt DM, Saseen JJ, Tillman DJ, Wilkinson DS. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. *Pharmacotherapy*. 2000;20(10):1159-1166.
19. Ageno W, Garcia D, Silingardi M, Galli M, Crowther M. A randomized trial comparing 1 mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves. *J Am Coll Cardiol*. 2005;46(4):732-733.
20. Ageno W, Crowther M, Steidl L, et al. Low dose oral vitamin K to reverse acenocoumarol-induced coagulopathy: a randomized controlled trial. *Thromb Haemost*. 2002;88(1):48-51.
21. Crowther MA, Ageno W, Garcia D, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. *Ann Intern Med*. 2009;150(5):293-300.
22. Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. *Ann Intern Med*. 2002;137(4):251-254.
23. Fondevila CG, Grosso SH, Santarelli MT, Pinto MD. Reversal of excessive oral anticoagulation with a low oral dose of vitamin K1 compared with acenocoumarin discontinuation. A prospective, randomized, open study. *Blood Coagul Fibrinolysis*. 2001;12(1):9-16.
24. Crowther MA, Julian J, McCarty D, et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. *Lancet*. 2000;356(9241):1551-1553.
25. Crowther MA, Garcia D, Ageno W, et al. Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Results of a prospective cohort study. *Thromb Haemost*. 2010;104(1):118-121.
26. Pengo V, Banzato A, Garelli E, Zasso A, Biasiolo A. Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. *Blood Coagul Fibrinolysis*. 1993;4(5):739-741.
27. Hung A, Singh S, Tait RC. A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization. *Br J Haematol*. 2000;109(3):537-539.

28. Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. *Arch Intern Med.* 1999;159(22):2721-2724.
29. Nee R, Doppenschmidt D, Donovan DJ, Andrews TC. Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. *Am J Cardiol.* 1999;83(2):286-288, A6-A7.
30. Mounce M, Essel C, Kim T, Harris CM. Risk factors for bleeding in hospitalized patients with elevated INR: no vitamin K therapy received versus vitamin K received. *Hosp Pharm.* 2015;50(10):894-899.
31. Lousberg TR, Witt DM, Beall DG, Carter BL, Malone DC. Evaluation of excessive anticoagulation in a group model health maintenance organization. *Arch Intern Med.* 1998;158(5):528-534.